Mesoblast (MSB) Q1 2027 earnings summary

Executive summary

• Q1 FY2027 RYONCIL net revenue was US$28m, up 44% YoY; net operating cash spend was US$2.1m, an 86% improvement, and quarter-end cash was US$98.545m.

• Clinical and regulatory progress included completing treatment in the 350-patient chronic low back pain Phase 3 trial and FDA alignment on a planned LVAD-related BLA.

Financial highlights

• RYONCIL net revenue was US$28m, up 44% YoY; September had the quarter’s highest monthly new patient starts after expected July–August seasonal scheduling effects.

• Net operating cash used was US$2.128m, versus US$14.9m in the prior-year period; the reported improvement was 86%.

• Operating cash receipts were US$35.433m; payments included US$8.148m for R&D, US$7.356m for pre-commercial manufacturing development and US$9.695m for product manufacturing and operating costs.

• Cash and cash equivalents declined from US$102.914m at quarter start to US$98.545m at quarter end.

Outlook and guidance

• The adult SR-aGvHD RYONCIL registration trial commenced enrollment; up to 40 U.S. sites are expected to activate this year, representing ~60% of the ~8,500 annual U.S. adult allogeneic bone marrow transplant population.

• All patients in the 350-patient chronic low back pain Phase 3 trial completed treatment; results on its 12-month durable pain-reduction primary endpoint are expected next year.

• Formal FDA meeting minutes on the planned rexlemestrocel-L BLA were expected shortly.